866-997-4948(US-Canada Toll Free)

Iressa (Non Small Cell Lung Cancer)-Analysis and Forecasts to 2020

Published By :

GlobalData

Published Date : Oct 2011

Category :

Non Small Cell Lung Cancer

No. of Pages : 36 Pages

 

GlobalDatas pharmaceuticals report, Iressa (Non Small Cell Lung Cancer)-Analysis and Forecasts to 2020 provides Crizotinib salesforecasts for US. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2002-2020). The report also includes information on Non-Small Cell Lung Cancer market. This report is built using data and information sourced from GlobalDatas proprietary databases, primary and secondary research using Companys corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together with in-house analysis, by GlobalData\'s team of industry experts.

 

Note: This is a on-demand report and will be delivered within 7 business days (excluding weekends) of the purchase.

 

Scope

  • Therapy area profile including patient population for the US, EU5 and Japan (seven major markets)
  • Analysis and review of Iressa including historical sales data
  • Qualitative and quantitative assessment of market space
  • Analysis of the trends, drivers and restraints shaping and defining the markets
  • In-depth analysis of Stalevo including efficacy, safety, pricing, competition and other details which influence its sales potential
  • Detailed sales forecast for 2011-2020 for Iressa in each of the seven major markets

Reasons to buy

  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of competition by understanding the changing competitive landscape
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of the drugs performance 
  • Examine the historical sales performance of a drug in seven major markets
  • Obtain sales forecast for currently marketed/pipeline drug for 2011-2020 for all seven major markets

Table of Contents

 

1 Table of contents 2
1.1 List of Tables 3
1.2 List of Figures 3


2 Introduction 5
2.1 NSCLC Market 5
2.2 Epidemiology 5
2.3 Etiology 7
2.3.1 Tobacco 7
2.3.2 Radon 7
2.3.3 Asbestos 8
2.3.4 Other Environmental Agents 8
2.4 GlobalData Market Forecasts Report Guidance 9


3 NSCLC Disease Market: Market Characterization 10
3.1 NSCLC Disease Market 10
3.2 NSCLC Disease Market Forecast and CAGR 10
3.3 Drivers for the NSCLC Disease Market 11
3.3.1 High Incidence 11
3.3.2 High Mortality Rate 12
3.3.3 Increased Use of Chemotherapy 12
3.3.4 Emergence of Targeted Drugs and Maintenance Therapies 12
3.3.5 Promising Pipeline Drugs 12


4 Tumor-Node-Metastases (TNM) Classification of NSCLC 13


5 Iressa 16
5.1 Introduction 16
5.2 Mechanism of Action 16
5.3 Clinical Studies 16
5.4 Approval History of Iressa 17
5.5 Factors affecting Sales 18
5.5.1 Reporting of Interstitial Lung Disease (ILD) in Japan 18
5.5.2 Results of ISEL Study 18
5.5.3 Oral Administration 19
5.5.4 Absence of Competition in Third Line of Treatment of Advanced NSCLC 19
5.6 Drug Risk Benefit Score 19
5.6.1 Efficacy 19
5.6.2 Safety 19
5.6.3 Compliance 20
5.6.4 Dosing Convenience 20
5.7 Intensity of Competition 20
5.8 Sales forecast 20
5.8.1 Target patient Pool of Iressa 20
5.8.2 Dosing 22
5.8.3 Market Penetration 22
5.8.4 Annual Cost of Therapy 22
5.8.5 Sales Projection of Iressa 22


6 Appendix 32
6.1 Market Definitions 32
6.2 Abbreviations 32
6.3 Research Methodology 32
6.3.1 Coverage 33
6.3.2 Secondary Research 33
6.3.3 Forecasting 33
6.3.4 Number of Patients Approved to take the Drug 34
6.3.5 Net Penetration of Drug 34
6.3.6 Net Annual Dosing 35
6.3.7 Annual Cost of Therapy 35
6.3.8 Primary Research 35
6.3.9 Expert Panels 36
6.4 Contact Us 36
6.5 Disclaimer 36
6.6 Sources 36

List of Table


Table 1: NSCLC Incidence and Mortality,20082030 6
Table 2: NSCLC, Global Market Size Forecast ($bn),20092020 10
Table 3: Results of INTEREST Study 16
Table 4: Results of IPASS 17
Table 5: Approval of Iressa by indication 17
Table 6: Approval History of Iressa 18
Table 7: Drug Risk Benefit Score of Iressa 19
Table 8: Annual Cost of Therapy of Iressa 22
Table 9: Iressa,NSCLC, Global, Sales Forecast ($m),20022009 23
Table 10: Iressa,NSCLC, Global, Sales Forecast ($m),20102020 23
Table 11: Iressa,NSCLC, The US, Sales Forecast ($m),20032009 24
Table 12: Iressa,NSCLC, The US, Sales Forecast ($m),20102020 24
Table 13: Iressa,NSCLC, The UK, Sales Forecast ($m),20092020 25
Table 14: Iressa,NSCLC, France, Sales Forecast ($m),2009-2020 26
Table 15: Iressa,NSCLC, Germany, Sales Forecast ($m),2009-2020 27
Table 16: Iressa,NSCLC, Italy, Sales Forecast ($m),2009-2020 28
Table 17: Iressa,NSCLC, Spain, Sales Forecast ($m),2009-2020 29
Table 18: Iressa,NSCLC, Japan, Sales Forecast ($m),20022009 30
Table 19: Iressa,NSCLC, Japan, Sales Forecast ($m),20102020 30

List of Chart


Figure 1: Percentage Distribution of the Top 20 Cancers 5
Figure 2: Difference of % Distribution of Incidence and Mortality of Top 20 Cancers 6
Figure 3: Percentage Distribution of Different Types of NSCLC according to Incidence, 2008 7
Figure 4: % Share of Risk Factors for NSCLC in Developed Countries 8
Figure 5: Per Capita Cigarette Consumption, The US, 1976-2006 9
Figure 6: NSCLC, Global, Market Size Forecast ($bn), 20092020 10
Figure 7: Oncology,Global,Incidence(in million),20082030 11
Figure 8: NSCLC, Global, Incidence(in million),20082030 11
Figure 9: Broad Classification of NSCLC 13
Figure 10: Detailed TNM Classification 14
Figure 11: Classification of NSCLC 15
Figure 12: Drug Model Diagram of Iressa in The US and Japan 21
Figure 13: Drug Model Diagram of Iressa in EU 21
Figure 14: Iressa,NSCLC, Global, Sales Forecast ($m),20022020 23
Figure 15: Iressa,NSCLC, The US, Sales Forecast ($m),2003-2020 24
Figure 16: Iressa,NSCLC, The UK, Sales Forecast ($m),2009-2020 25
Figure 17: Iressa,NSCLC, France, Sales Forecast ($m),2009-2020 26
Figure 18: Iressa,NSCLC, Germany, Sales Forecast ($m),2009-2020 27
Figure 19: Iressa,NSCLC, Italy, Sales Forecast ($m),2009-2020 28
Figure 20: Iressa,NSCLC, Spain, Sales Forecast ($m),2009-2020 29
Figure 21: Iressa,NSCLC, Japan, Sales Forecast ($m),2002-2020 30
Figure 22: Iressa,NSCLC,Global Sales Distribution by Country ($m), 2020 31
Figure 23: GlobalData Methodology 32
Figure 24: Drug Model Diagram 34
Figure 25: Patients Approved to take the Drug 35

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *